V J O'Neill

474 total citations
11 papers, 388 citations indexed

About

V J O'Neill is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, V J O'Neill has authored 11 papers receiving a total of 388 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 4 papers in Pulmonary and Respiratory Medicine and 3 papers in Surgery. Recurrent topics in V J O'Neill's work include Colorectal Cancer Treatments and Studies (4 papers), Cancer Treatment and Pharmacology (4 papers) and Cancer and Skin Lesions (2 papers). V J O'Neill is often cited by papers focused on Colorectal Cancer Treatments and Studies (4 papers), Cancer Treatment and Pharmacology (4 papers) and Cancer and Skin Lesions (2 papers). V J O'Neill collaborates with scholars based in United Kingdom and United States. V J O'Neill's co-authors include Chris Twelves, P. Vasey, S.B. Kaye, G. Pentheroudakis, O.O. Melnyk, David A. Ramies, Roy S. Herbst, Alan Sandler, Jo Ann Davis and Louis Fehrenbacher and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and European Journal of Cancer.

In The Last Decade

V J O'Neill

10 papers receiving 371 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
V J O'Neill United Kingdom 7 164 120 99 80 59 11 388
Elena Collovà Italy 8 155 0.9× 140 1.2× 45 0.5× 25 0.3× 39 0.7× 23 352
Iyar Mazar United States 9 93 0.6× 49 0.4× 66 0.7× 37 0.5× 37 0.6× 20 313
Helga Lipari Italy 8 131 0.8× 56 0.5× 31 0.3× 25 0.3× 46 0.8× 14 258
Jeroen S. Kloover Netherlands 12 229 1.4× 162 1.4× 71 0.7× 40 0.5× 2 0.0× 21 523
Calogero Buscarino Italy 5 88 0.5× 47 0.4× 33 0.3× 24 0.3× 39 0.7× 7 194
Dominic A. Solimando United States 9 128 0.8× 37 0.3× 60 0.6× 50 0.6× 8 0.1× 90 344
Gerlie Gieser United States 4 100 0.6× 81 0.7× 152 1.5× 82 1.0× 3 0.1× 4 463
Scott A. Soefje United States 8 139 0.8× 35 0.3× 71 0.7× 39 0.5× 21 0.4× 29 369
Andrea Pujol Nicolas France 7 395 2.4× 160 1.3× 127 1.3× 16 0.2× 17 0.3× 11 659
Sam C. Augustine United States 10 88 0.5× 43 0.4× 115 1.2× 36 0.5× 45 0.8× 14 490

Countries citing papers authored by V J O'Neill

Since Specialization
Citations

This map shows the geographic impact of V J O'Neill's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by V J O'Neill with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites V J O'Neill more than expected).

Fields of papers citing papers by V J O'Neill

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by V J O'Neill. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by V J O'Neill. The network helps show where V J O'Neill may publish in the future.

Co-authorship network of co-authors of V J O'Neill

This figure shows the co-authorship network connecting the top 25 collaborators of V J O'Neill. A scholar is included among the top collaborators of V J O'Neill based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with V J O'Neill. V J O'Neill is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Macklin, Denise, et al.. (2019). A retrospective analysis of Hickman line-associated complications in patients with solid tumor undergoing infusional chemotherapy..
2.
Karapetis, Christos S., P. Clingan, N. B. Leighl, et al.. (2010). Phase II study of PRO95780 plus paclitaxel, carboplatin, and bevacizumab (PCB) in non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 28(15_suppl). 7535–7535. 15 indexed citations
3.
Alberti, Dona, Kate Oliver, Noelle K. LoConte, et al.. (2009). A phase I study of capecitabine, oxaliplatin (CapOx), and lapatinib (L) in metastatic or advanced solid tumors. Journal of Clinical Oncology. 27(15_suppl). 2579–2579. 1 indexed citations
5.
O'Neill, V J & J Cassidy. (2005). Capecitabine in the Treatment of Colorectal Cancer. Future Oncology. 1(2). 183–190. 6 indexed citations
6.
O'Neill, V J, S.B. Kaye, Nicholas Reed, et al.. (2002). A dose-finding study of carboplatin–epirubicin–docetaxel in advanced epithelial ovarian cancer. British Journal of Cancer. 86(9). 1385–1390. 6 indexed citations
7.
O'Neill, V J & Chris Twelves. (2002). Oral cancer treatment: developments in chemotherapy and beyond. British Journal of Cancer. 87(9). 933–937. 221 indexed citations
9.
Pentheroudakis, G., V J O'Neill, P. Vasey, & S.B. Kaye. (2001). Spontaneous acute tumour lysis syndrome in patients with metastatic germ cell tumours. Supportive Care in Cancer. 9(7). 554–557. 41 indexed citations
10.
O'Neill, V J, et al.. (1997). Audit of oxygen therapy.. PubMed. 51(4). 217–8. 9 indexed citations
11.
O'Neill, V J, T.R. Jeffry Evans, & S.B. Kaye. (1997). An audit of Hickman line complications in patients with solid tumours. European Journal of Cancer. 33. S54–S54. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026